Learn about featured Cancer clinical trials currently enrolling, or search our Cancer clinical trials database for all open and accruing studiesRead More
Cleveland Clinic researchers studying renal cell carcinoma patients whose cancer returned after nephrectomy have identified a set of genes strongly associated with recurrence. The prognostic gene assay should help clinicians decide how to manage localized renal masses.
Investigators are analyzing microbiomes in several solid tumors. If microbiome elements are involved in carcinogenesis, they could serve as biomarkers for progression and prognosis, as well as therapeutic targets.
A new combination epigenetic therapy could enhance activity of immune checkpoint inhibitors in lung cancer. A proof-of-concept trial of oral tetrahydrouridine (THU)-decitabine, along with nivolumab, will begin soon at Cleveland Clinic.
Several promising antibody-based treatment strategies are in development for acute lymphoblastic leukemia and acute myeloid leukemia. These could change the decade-old treatment paradigm.
New Cleveland Clinic research shows that serial hepatic USG — paired with confirmatory CT/MRI scans when needed — has high sensitivity and specificity for detecting asymptomatic uveal melanoma metastases.
Cleveland Clinic researchers find overly stringent eligibility criteria relevant to expected and observed adverse events may exclude specific patient populations from randomized clinical trials of hematologic malignancies.
New guidelines drafted by a Cleveland Clinic-led expert panel should speed the development and approval of advanced statistical tools to more accurately predict cancer’s course in individual patients.
Most cases of adult myeloid neoplasms, including myelodysplastic syndromes (MDS), have been presumed to occur sporadically. But Cleveland Clinic researchers identified a mutated gene, DDX41, associated with development of MDS, supporting the prospect of a familial predisposition mechanism behind such malignancies.
President Obama’s final State of the Union speech unveiled a “cancer moonshot” initiative to greatly accelerate progress against the disease. Cleveland Clinic Taussig Cancer Institute Chairman Brian J. Bolwell, MD, offers a step-by-step prescription to make it work.
Cleveland Clinic Cancer Center leaders Brian J. Bolwell, MD, and Alok Khorana, MD, say it’s time for the oncology community to embrace patient-centered value measures and improvements.